AUG 0 3 2001

Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to r espond to a collection of information unless it displays a valid OMB control number.

Complete if Known

Application Number 09/599,274

Filing Date June 22, 2000

First Named Inventor Garrill

Examiner Name J. Foster

Group Art Unit 3728

Attorney Docket No. PG4114

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

\$110.00

METHOD OF PAYMENT	FEE CALCULATION (continued)							
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES Large Entity Small Entity							
Deposit Account 07-1392	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee	Description	on	Fee Paid
Number	105	130	205	65	Surcharge - late	-		
Deposit Account Name GlaxoSmithKline	127	50	227	25	sheet		filing fee or cover	
Charge Any Additional Fee Required	139	130	139	130	Non - English sp	pecification		
Under 37 CFR §§ 1.16 and 1.17	147	2,520	147	2,520	For filing a requ	est for <i>ex pa</i>	rte reexamination	
Applicant claims small entity status. See 37 CFR § 1.27	112	920*	112	920°	action		IR prior to Examiner	
2. Payment Enclosed:	113	1,840*	113	1,840*	Requesting pub action	lication of S	IR after Examiner	
Check Credit card Money Other	115	110	215	55		ply within fir	st month	
FEE CALCULATION	116	390	216	195	Extension for re	ply within se	cond month	
1. BASIC FILING FEE	117	890	217	445	Extension for re	ply within thi	ird month	
Large Entity Small Entity	118	1,390	218	695	Extension for re	ply within fo	urth month	
Fee Fee Fee Fee Description	128	1,890	228	945	Extension for re	ply within fift	th month	
Code (\$) Code (\$) Fee Paid 101 710 201 355 Utility filing fee	119	310	219	155	Notice of Appea	ıl		
106 320 206 160 Design filing fee	120	310	220	155	Filing a brief in support of an appeal			
107 490 207 245 Plant filing fee	121	270	221	135	Request for oral hearing			
108 710 208 355 Reissue filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding			
114 150 214 75 Provisional filing fee	140	110	240	55	Petition to revive - unavoidable			
SUBTOTAL (1)	141	1,240	241	620	Petition to revive - unintentional			
`` \	142	1,240	242	620	Utility issue fee	(or reissue)	. 4	
2. EXTRA CLAIM FEES Fee from	143	440	243	220	Design issue fee	е	7C	
Extra Claims Delow Fee Paid		600	244	300	Plant issue fee		er S	
		130	122	130	Petitions to the	Commission	370	
		50	123	50	Processing fee under 37 CFR § 197(q)			
Large Entity Small Entity	126	180	126	180	Submission of It Statement	nformation [Disclosure	
Fee Fee Fee Fee Description Code (\$) Code (\$)	581	40	581	40	Recording each (times number of	patent assi	gnment per property	
103 18 203 9 Claims in excess of 20 102 80 202 40 Independent claims in excess of 3	146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))			
104 270 204 135 Multiple dependent claim, if not paid	149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))			
109 80 209 40 ** Reissue independent claims	179	710	279	355	Request for Continued Examination (RCE)			
over original patent 110 18 210 9 ** Reissue claims in excess of 20	169 900 169 900 Request for expedited examination of a design application							
and over original patent	Oth	Other fee (specify) Terminal Disclaimer Fee under 37 CFR 1.20(d) 110.0						
SUBTOTAL (2) \$0.00	·							
**or number previously paid, if greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) \$110.00							
SUBMITTED BY Complete (if applicable)								
Name (Print/Type) Christopher P. Rogers		Registration No. (Attorney/Agent) 36,334			36,334	Telephone	(919) 483-	1240
Signature Www Plogn						Date	3 angus	2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

Docket Number (Optional)

REJECTION OVER A PRIOR PATENT	PG4114					
In re Application of: Garrill et al.	•					
Application No.: 09/599,274						
Filed: June 22, 2000	. •					
For: METHOD AND PACKAGE FOR STORING A PRESSURIZED CONTAINER CONTAINING A DRUG						
The owner*, SmithKline Beecham, of 100 percent interes hereby disclaims, except as provided below, the terminal part of the statutory term of instant application, which would extend beyond the expiration date of the full statuto C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of 6,119,853. The owner hereby agrees that any patent so granted on the interest enforceable only for and during such period that it and the prior patent are common runs with any patent granted on the instant application and is binding upon the assigns. In making the above disclaimer, the owner does not disclaim the terminal patent instant application that would extend to the expiration date of the full statutory te 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer: expires for failure to pay a maintenance fee, is held unenforceable, is for competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed unclaims canceled by a reexamination certificate, is reissued, or is in any manner expiration of its full statutory term as presently shortened by any terminal disclaimer.	ry term defined in 35 U.S. If prior Patent No. Istant application shall be ally owned. This agreement grantee, its successors or art of any patent granted on as defined in 35 U.S.C. claimer, in the event that it bund invalid by a court of der 37 CFR 1.321, has all					
Check either box 1 or 2 below, if appropriate.						
1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.						
I hereby declare that all statements made herein of my own knowledge are to made on information and belief are believed to be true; and further that these states knowledge that willful false statements and the like so made are punishable by fine under Section 1001 of Title 18 of the United States Code and that such willful false state validity of the application or any patent issued thereon.	nents were made with the or imprisonment, or both,					
2. X The undersigned is an attorney or agent of record.	3 and 12001					
AZERGAW1 00000032 071392 09599274 Signature	Date = [
110.00 CH Signature	See CE					
Christopher P. Rogers	W 6 W					
Typed or printed name	CEIVEL					
Terminal disclaimer fee under 37 CFR 1.20(d) included.	Date -9 2001 ROOM Should not					
Terminal disclaimer fee under 37 CFR 1.20(d) included. WARNING: Information on this form may become public. Credit card information should not						
be included on this form. Provide credit card information and authorization on P	TO-2038.					
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (ow Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	ner).					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Express Mail EL395889605US

08/09/200 01 FC:148